Results 41 to 50 of about 2,758 (199)

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Haematologica, 2020
Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11%-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab.
Robert A. Brodsky, Régis Peffault de Latour, Scott T. Rottinghaus, Alexander Röth, Antonio M. Risitano, Ilene C. Weitz, Peter Hillmen, Jaroslaw P. Maciejewski, Jeff Szer, Jong Wook Lee, Austin G. Kulasekararaj, Lori Volles, Andrew I. Damokosh, Stephan Ortiz, Lori Shafner, Peng Liu, Anita Hill, Hubert Schrezenmeier   +17 more
doaj   +1 more source

Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

BMC Nephrology, 2021
Background Atypical hemolytic uremic syndrome (aHUS) triggered by pregnancy is a rare disease caused by dysregulation of the alternative complement pathway that occurs in approximately 1 in 25,000 pregnancies.
Anja Gäckler, Ulf Schönermarck, Vladimir Dobronravov, Gaetano La Manna, Andrew Denker, Peng Liu, Maria Vinogradova, Sung-Soo Yoon, Manuel Praga   +8 more
doaj   +1 more source

Real-world evidence from the Global aHUS Registry confirms the safety and effectiveness of switching to ravulizumab from eculizumab in patients with aHUS: a plain language summary [PDF]

Registry; Atypical hemolytic uremic syndrome; RavulizumabRegistre; Síndrome hemolític urèmic atípic; RavulizumabRegistro; Síndrome hemolítico urémico atípico; RavulizumabWhat is aHUS?
Al-Dakkak, Imad, Ariceta Iraola, Gema, Greenbaum, Larry, Schaefer, Franz   +3 more
core   +1 more source

The inhibition of complement system in formal and emerging indications: results from parallel one-stage pairwise and network meta-analyses of clinical trials and real-life data studies [PDF]

, 2020
Producción CientíficaThis manuscript presents quantitative findings on the actual effectiveness of terminal complement component 5 (C5) inhibitors and complement component 1 (C1) esterase inhibitors through their formal and common “off-label ...
Adler, Marcel, Bernuy Guevara, Coralina Melissa, Cachat, François, Chehade, Hassib, Guzzo, Gabriella, Herrera Gómez, Francisco Magno, Lizaraso Soto, Frank, Martín García, Débora, Muller, Yannick D., Ochoa Sangrador, Carlos, Pascual, Manuel, Paz Fernández, Félix Jesús de, Teta, Daniel, Vionnet, Julien, Álvarez González, Francisco Javier   +14 more
core   +1 more source

Monoclonal antibodies in COVID-19 management: a scoping review [PDF]

, 2021
Coronavirus disease 2019 (COVID-19) was declared as pandemic on March 11th 2020 by the world health organization (WHO). Vaccination is for preventing COVID-19 morbidity but when people are infected, treatment is required and even after one and half years
Adaikkalavan, Umayal, Cherumanalil, Jeeja Mathummal, Pannikkottuthodi, Salwa, Poovancheri, Hasna   +3 more
core   +2 more sources

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

PLoS ONE, 2020
BackgroundEculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains a high treatment burden.
John Devin Peipert, Austin G Kulasekararaj, Anna Gaya, Saskia M C Langemeijer, Susan Yount, F Ataulfo Gonzalez-Fernandez, Emilio Ojeda Gutierrez, Christa Martens, Amy Sparling, Kimberly A Webster, David Cella, Ioannis Tomazos, Masayo Ogawa, Caroline I Piatek, Richard Wells, Flore Sicre de Fontbrune, Alexander Röth, Lindsay Mitchell, Anita Hill, Karen Kaiser   +19 more
doaj   +1 more source

Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. [PDF]

, 2021
Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a life-threatening syndrome that occurs in adult and pediatric patients after hematopoietic stem cell transplantation.
Daha, Mohamed, Dudler, Thomas, Fujita, Teizo, Gavriilaki, Eleni, Ho, Vincent T, Jodele, Sonata, Schwaeble, Wilhelm   +6 more
core   +2 more sources

Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

Frontiers in Neurology
ObjectiveTo assess the pharmacokinetics and pharmacodynamics of the long-acting terminal complement 5 (C5) inhibitor ravulizumab in adults with anti-aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) in the phase 3, open-
Stephan Ortiz, Sean J. Pittock, Achim Berthele, Michael Levy, Ichiro Nakashima, Celia Oreja-Guevara, Celia Oreja-Guevara, Kerstin Allen, Yasmin Mashhoon, Becky Parks, Ho Jin Kim   +10 more
doaj   +1 more source

Guideline for the management of myasthenic syndromes [PDF]

, 2023
Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndromes (CMS) represent an etiologically heterogeneous group of (very) rare chronic diseases.
Abicht, Angela, Chan, Andrew, Della Marina, Adela, Hagenacker, Tim, Hekmat, Khosro, Hoffmann, Hans-Stefan, Hoffmann, Sarah, Jander, Sebastian, Keller, Christian, Marx, Alexander, Meisel, Andreas, Melms, Arthur, Melzer, Nico, Müller-Felber, Wolfgang, Pawlitzki, Marc, Rückert, Jens-Carsten, Schneider-Gold, Christiane, Schoser, Benedikt, Schreiner, Bettina, Schroeter, Michael, Schubert, Bettina, Sieb, Jörn-Peter, Wiendl, Heinz, Zimprich, Fritz   +23 more
core   +1 more source

Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence

Neuropsychiatric Disease and Treatment, 2023
Tuan Vu,1 Heinz Wiendl,2 Masahisa Katsuno,3 Stephen W Reddel,4 James F Howard Jr5 1Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA; 2Department of Neurology with Institute of Translational Neurology ...
Vu T, Wiendl H, Katsuno M, Reddel SW, Howard JF Jr   +4 more
doaj